Pyruvate dehydrogenase deficiency arises from genetic alterations affecting one of several components of the mitochondrial PDH complex, with the specific subunit affected determining the clinical subtype and its inheritance pattern. For the E3 subtype (dihydrolipoamide dehydrogenase deficiency), the underlying cause follows an autosomal recessive inheritance pattern: two altered gene copies, one inherited from each parent, are required to produce the condition. In families where both parents carry one altered copy, each pregnancy carries a 25% probability of an affected child; heterozygous carriers are not expected to develop the disorder. The E3 subtype has a higher carrier frequency in Ashkenazi Jewish populations compared with the general population. Inheritance patterns for other subtypes of PDH complex deficiency—including those involving the E1-alpha subunit, which can be inherited in an X-linked manner—differ from the E3 autosomal recessive pattern; specific inheritance data for individual subtypes other than E3 are not consolidated within this packet. Metabolic decompensation is commonly precipitated by fasting, infection, catabolic stress, or dietary factors.

No formal clinical diagnostic criteria have been established for pyruvate dehydrogenase deficiency. Diagnosis is supported by a combination of clinical presentation and biochemical laboratory findings. In the early-onset neurological form, characteristic laboratory features include metabolic acidosis, elevated plasma lactate, and hypoglycemia. Elevated urine alpha-ketoglutarate and elevated plasma branched-chain amino acids may indicate dysfunction extending to additional metabolic enzyme complexes, as seen in certain subtypes. Liver function tests may reveal transaminase elevation or hepatic failure in those with the hepatic presentation. Creatine kinase levels, ranging from normal to markedly elevated, may be observed in individuals with myopathic involvement. Newborn screening using dried blood spot citrulline measurements may occasionally lead to identification of some cases; however, screening has not reliably identified asymptomatic individuals, and the condition is not included on most standard newborn screening panels. Neurological evaluation including brain imaging may be performed to assess for structural changes. Cardiac evaluation and ophthalmological assessment are relevant depending on the clinical presentation.

No treatments specifically approved by the FDA are identified in this packet for pyruvate dehydrogenase deficiency. Management is directed at reducing the frequency and severity of metabolic decompensation episodes and addressing complications across affected organ systems. A multidisciplinary care model is central to management, including input from metabolic disease specialists and nutritionists.

For the E3 subtype (dihydrolipoamide dehydrogenase deficiency), published clinical experience describes several therapeutic strategies, though consensus management recommendations do not currently exist and clinical response varies among individuals. Protein and branched-chain amino acid restriction has been employed, with some individuals demonstrating biochemical or clinical improvement. Ketogenic and high-fat dietary approaches have been used in individuals with PDH complex deficiency, including the E3 subtype, with variable outcomes across reported cases; some individuals have benefited while others have experienced adverse effects. Dichloroacetate (DCA), which acts to sustain PDH complex activity by inhibiting its regulatory kinase, has demonstrated transient reductions in lactic acid levels in some reported cases; prolonged use has been associated with peripheral neuropathy. Additional agents explored in the E3 subtype with limited evidence of benefit include thiamine, coenzyme Q10, lipoic acid, riboflavin, and biotin.

During acute metabolic crises, clinical priorities include addressing precipitating factors such as infection or fasting and providing appropriate nutritional support. Persistent feeding difficulties may necessitate assisted feeding measures. Developmental, physical, occupational, and speech therapy are employed as indicated by the extent of neurological involvement.

The prognosis of pyruvate dehydrogenase deficiency is highly variable and is shaped by the specific subtype, severity of enzyme deficiency, and predominant clinical presentation. In the early-onset neurological form of the E3 subtype, affected infants frequently do not survive their initial metabolic decompensation episode, or die within the first one to two years of life during a recurrent episode. Children who survive beyond the early years often exhibit residual neurological impairment including intellectual disability, spasticity, ataxia, and seizures, as well as growth deficiencies. The multiple treatment strategies that have been attempted in the early-onset neurological form have not demonstrated significant alteration of the natural history of the disease. Individuals with a predominantly hepatic presentation and preserved neurological function between acute episodes may follow a different trajectory, though recurrent metabolic crises carry ongoing risk. The myopathic presentation may be associated with a more variable clinical course.

Pyruvate dehydrogenase deficiency is an active area of clinical research. Several clinical trials are currently recruiting participants, investigating a range of therapeutic approaches. Active investigations include a Phase 2 study evaluating glycerol phenylbutyrate in individuals with pyruvate dehydrogenase deficiency, a Phase 1 study examining triheptanoin in children with primary PDH complex deficiency, and a Phase 3 trial of dichloroacetate. Gene therapy is among the intervention types under active investigation. Natural history data are also being collected through ongoing registry and observational studies. The published research landscape for this condition spans basic science, preclinical studies, case reports, and review literature, with biomarker research and gene therapy representing themes of active interest. Individuals and families interested in current trial opportunities can search the ClinicalTrials.gov database.